Indication

Adjunct therapy for partial-onset seizure associated with tuberous sclerosis

Partial-onset seizures associated with tuberous sclerosis complex (TSC) are localized epileptic events arising within the central nervous system, originating from a discrete cerebral hemisphere or localized neural network. Read more about Adjunct therapy for partial-onset seizure associated with tuberous sclerosis

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Adjunct therapy for partial-onset seizure associated with tuberous sclerosis therapies.

Showing 1–2 of 2 drugs

EVEROLIMUS

ANTINEOPLASTIC - MTOR KINASE INHIBITORS·SUBEPENDYMAL GIANT CELL ASTROCYTOMA ASSOCIATED WITH TUBEROUS SCLEROSIS·+1
Amneal Pharmaceuticals

AFINITOR DISPERZ (everolimus)

ANTINEOPLASTIC - MTOR KINASE INHIBITORS·SUBEPENDYMAL GIANT CELL ASTROCYTOMA ASSOCIATED WITH TUBEROUS SCLEROSIS·+1
Novartis Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Adjunct therapy for partial-onset seizure associated with tuberous sclerosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Adjunct therapy for partial-onset seizure associated with tuberous sclerosis.

Partial-onset seizures associated with tuberous sclerosis complex (TSC) are localized epileptic events arising within the central nervous system, originating from a discrete cerebral hemisphere or localized neural network.

They manifest clinically as focal sensory, motor, or autonomic episodes, with or without impaired awareness or progression to bilateral tonic-clonic activity.

In patients with TSC, this epileptogenesis typically stems from underlying cortical dysplasias, subependymal nodules, and cortical tubers driven by inactivating mutations in the *TSC1* or *TSC2* genes, which cause hyperactivation of the mammalian target of rapamycin (mTOR) signaling pathway.

When designated as an adjunct therapy indication, treatment is applied as an add-on intervention alongside other baseline antiseizure medications to control these focal seizures, which frequently prove refractory to monotherapy.

Personalize your experience

Follow Adjunct therapy for partial-onset seizure associated with tuberous sclerosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it